Amgen’s $28bn acquisition of Horizon Therapeutics has been given the go-ahead following a settlement with the Federal Trade Commission (FTC) and six states. The deal has conditions to maintain competition in two diseases where Horizon has a monopoly. It also involves restrictions on bundling in which a company provides greater rebates on certain drugs to boost the position of others. The practice’s restriction may have ensured the deal’s approval, according to Nathan Ray, a partner at healthcare consulting firm, West Monroe.
CISA urges orgs to review software after ‘Shai-Hulud’ supply chain compromise – The Record from Recorded Future News
CISA urges orgs to review software after ‘Shai-Hulud’ supply chain compromise The Record from Recorded Future News
